CD4CAR

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameCD4CAR
Drug Alias Nameanti-CD4 CAR T-cell therapy (iCell Gene Therapeutics)ICG-122CD4CAR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface antigen CD4 modulatorsT lymphocytes stimulantsImmunostimulants
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsMultiple MyelomaLymphoma, T-Cell, PeripheralMycosis Fungoides +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesiCell Gene Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, T-Cell, PeripheralMycosis Fungoides +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A